Patents by Inventor Gaoqiang Yang
Gaoqiang Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357221Abstract: Heterocyclic compounds of Formula I: and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.Type: ApplicationFiled: June 28, 2023Publication date: November 9, 2023Inventors: Yves GAREAU, Stéphane GINGRAS, Yves CHANTIGNY, Gaoqiang YANG, Guy SAUVAGEAU, Irène BACCELLI, Anne MARINIER
-
Patent number: 11760754Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.Type: GrantFiled: November 2, 2018Date of Patent: September 19, 2023Assignee: UNIVERSITÉ DE MONTRÉALInventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
-
Publication number: 20210387980Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.Type: ApplicationFiled: November 2, 2018Publication date: December 16, 2021Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
-
Publication number: 20210300932Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.Type: ApplicationFiled: March 26, 2021Publication date: September 30, 2021Inventors: Manuel Perez VAZQUEZ, M. Monzur MORSHED, Jennifer L. HICKEY, Adam Paul KAFAL, James GILLARD, Narendra PATEL, Sai Kumar CHAKKA, Andrew L. ROUGHTON, Marc-André POUPART, Gaoqiang YANG
-
Patent number: 11072616Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.Type: GrantFiled: November 14, 2016Date of Patent: July 27, 2021Assignees: Universite de Montreal, Zealand Pharma A/SInventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Adam Paul Kafal, James Gillard, Narendra Patel, Sai Kumar Chakka, Andrew L. Roughton, Marc-André Poupart, Gaoqiang Yang
-
Patent number: 11046695Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: GrantFiled: November 14, 2016Date of Patent: June 29, 2021Assignees: Zealand Pharma A/S, Universite de MontrealInventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
-
Patent number: 10981921Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: GrantFiled: August 4, 2020Date of Patent: April 20, 2021Assignee: Zealand Pharma A/SInventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
-
Publication number: 20200361944Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Inventors: Manuel Perez VAZQUEZ, M. Monzur MORSHED, Jennifer L. HICKEY, Marc-André POUPART, Gaoqiang YANG, James GILLARD, Adam Paul KAFAL, Andrew L. ROUGHTON
-
Publication number: 20200165300Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.Type: ApplicationFiled: November 14, 2016Publication date: May 28, 2020Inventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Adam Paul Kafal, James Gillard, Narendra Patel, Sai Kumar Chakka, Andrew L. Roughton, Marc-André Poupart, Gaoqiang Yang
-
Publication number: 20190077805Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.Type: ApplicationFiled: November 14, 2016Publication date: March 14, 2019Inventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
-
Publication number: 20170326233Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an anti-body moiety), pharmaceutical compositions, kits (e.g.Type: ApplicationFiled: November 13, 2015Publication date: November 16, 2017Inventors: Michel Demeule, Christian Che, Sanjoy Das, Gaoqiang Yang
-
Publication number: 20170281787Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an antibody moiety), pharmaceutical compositions, kits (e.g.Type: ApplicationFiled: November 11, 2016Publication date: October 5, 2017Inventors: Jean-Paul Castaigne, Gaoqiang Yang, Christian Che, Michel Demeule
-
Patent number: 9687561Abstract: The invention relates to dendrimers conjugated to multiple targeting peptides and one or more therapeutic, diagnostic, or imaging agents for delivery of such agents across the blood-brain barrier and into certain cell types including, cells expressing the LRP-1 receptor. Also described are methods of making compounds that comprise dendrimers conjugated to targeting peptides and therapeutic, diagnostic, or imaging agents.Type: GrantFiled: August 14, 2013Date of Patent: June 27, 2017Assignee: Angiochem Inc.Inventors: Michel Demeule, Alain Larocque, Gaoqiang Yang, Sasmita Tripathy
-
Publication number: 20160375145Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Inventors: Michel DEMEULE, Christian Che, Reinhard Gabathuler, Gaoqiang Yang
-
Publication number: 20160106856Abstract: The present invention relates to antibody-polypeptide-cytotoxin conjugates and methods of making, packaging, and using the conjugates. The polypeptide can be a Kunitz-type protease inhibitor or a derivative thereof that facilitates transport of the conjugate across the blood-brain barrier and/or into cancer cells outside the CNS, and the antibody moiety selectively binds a target within the CNS or in peripheral tumors to direct the cytotoxic agent to that target (e.g., a tumor or cancer cell). The conjugates can be further defined by the inclusion of a linker between the antibody moiety and the polypeptide; by the number of polypeptides and cytotoxic agents conjugated thereto; by the positions at which the entities within the conjugates are bound to one another; and by the larger configuration of the conjugate. Modified polypeptides (e.g., polypeptides conjugated to cytotoxic agents but not to an antibody moiety), pharmaceutical compositions, kits (e.g.Type: ApplicationFiled: August 14, 2013Publication date: April 21, 2016Inventors: Jean-Paul Castaigne, Gaoqiang Yang, Christian Che, Michel Demeule
-
Publication number: 20160015823Abstract: The invention relates to dendrimers conjugated to multiple targeting peptides and one or more therapeutic, diagnostic, or imaging agents for delivery of such agents across the blood-brain barrier and into certain cell types including, cells expressing the LRP-1 receptor. Also described are methods of making compounds that comprise dendrimers conjugated to targeting peptides and therapeutic, diagnostic, or imaging agents.Type: ApplicationFiled: August 14, 2013Publication date: January 21, 2016Inventors: Michel DEMEULE, Alain LAROQUE, Gaoqiang YANG, Sasmita TRIPATHY
-
Publication number: 20150038429Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.Type: ApplicationFiled: July 11, 2014Publication date: February 5, 2015Inventors: Michel DEMEULE, Christian Che, Reinhard Gabathuler, Gaoqiang Yang
-
Patent number: 8828925Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.Type: GrantFiled: October 15, 2009Date of Patent: September 9, 2014Assignee: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Reinhard Gabathuler, Gaoqiang Yang
-
Publication number: 20120135914Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4?-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment.Type: ApplicationFiled: October 15, 2009Publication date: May 31, 2012Applicant: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Reinhard Gabathuler, Gaoqiang Yang